The short answer
A rising count of adverse event reports for a newly marketed drug is expected and largely uninformative about risk. Exposure grows, awareness grows, and reporting itself follows a well-documented curve that peaks a few years after launch and then declines.
Key facts
- Observation
- Tirzepatide ketoacidosis reports in non-diabetics
- 2022 rate
- 1-2 cases per quarter
- 2025 rate
- 28-34 cases per quarter
- Tirzepatide US approval
- May 2022 (type 2 diabetes)
- Semaglutide US approvals
- 2017 (diabetes), 2021 (weight management)
- What is missing
- Number of people exposed in each quarter
- Named effect
- Weber effect / notoriety bias
- Correct interpretation
- A prompt for a denominator-based study
The observation, and why it looks alarming
Makhmutov and Qureshi analysed FAERS reports from January 2021 to December 2025 and found that ketoacidosis reports for tirzepatide in non-diabetic patients rose from one or two per quarter in 2022 to 28 to 34 per quarter by 2025, a fifteen- to thirty-fold increase over three years. Written as a headline, that reads as an escalating safety problem. Written with its denominator it reads as nothing much at all, and the denominator is what a spontaneous reporting system does not have.
Exposure is the first and largest explanation
Tirzepatide was first approved in the United States in May 2022. In the first quarter of that curve there were almost no people taking it. By 2025 there were millions. If the per-person risk were exactly constant, the raw count would still have risen by something close to the same factor as the prescription volume. A count that grows in step with uptake carries no information about whether the drug became more dangerous, and separating the two requires a denominator that FAERS cannot supply.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Reporting behaviour has its own curve
Beyond exposure, reporting rates for a given drug are not stable over time. The pattern usually called the Weber effect describes reporting for a newly marketed drug rising for roughly the first two years and then declining, independent of any change in the underlying risk. Layered on top is notoriety bias: once an association is discussed in the literature or the press, clinicians who see the event start attributing it to the drug and reporting it, which increases counts for a reason that is entirely about attention. A drug approved in 2022 and a drug approved in 2017 sit at different points on both curves at any given moment, which is one of the strongest reasons not to compare their raw counts.
What the same paper's controlled comparison shows
The disproportionality analysis in that paper is the part that carries information, because it normalises against the rest of the database. Semaglutide showed a ketoacidosis reporting odds ratio of 3.15 (95% CI 2.78 to 3.56); tirzepatide showed 1.22 (95% CI 1.06 to 1.39). Both are above one and both are statistically distinguishable from it, so both drugs have a signal. But the drug whose raw count was climbing fastest has the smaller ratio, which is what you would expect if the climbing count were mostly uptake. The trend line and the ratio point in opposite directions, and only one of them is adjusted for anything.
Where the counts do carry information
Two places. The proportion of reported cases that were serious is not affected by the missing denominator in the same way, because it is a ratio within the reported cases: hospitalisation was required in 74.3% of semaglutide cases and 71.3% of tirzepatide cases in that analysis, which says something real about the severity of the cases that do get reported, whatever their frequency. And an abrupt discontinuity (counts jumping in a period when exposure did not) is a real signal, because the usual explanations do not fit. A smooth rise tracking a product launch is not that.
The general rule
Any raw adverse event count for a recently launched drug should be read as a measure of how much the drug is being used and discussed, with a risk signal somewhere inside it that the count alone cannot isolate. The way to isolate it is a study with people in the denominator: a cohort, a case-control design, a self-controlled case series, or a health-record analysis where exposure time is measured. Those studies are slower, which is why the fast, biased number is the one that circulates first.
Frequently asked questions
Is euglycaemic ketoacidosis a real concern with these drugs?
Both agents showed statistically significant disproportionality signals in the analysis described here, and the reported cases were frequently serious. That is a reason for the question to be studied properly, which is what a signal is for. It is not, by itself, a measurement of how often it happens.
Why not just divide the reports by prescriptions?
People do try, and the result is called a reporting rate. It is better than nothing but still unreliable, because the fraction of true events that get reported is unknown, varies by drug, by country, by seriousness and over time. Dividing an unknown fraction by a known denominator does not produce a rate.
Does the Weber effect always hold?
It is a described pattern, not a law, and studies since the original description have found it holds for some drugs and periods and not others, particularly where a drug's use expands sharply years after launch, as has happened across this class. It is a reason for caution about time trends rather than a correction that can be applied.
How long before real risk estimates arrive?
For a drug launched in 2022, cohort studies with adequate follow-up begin appearing around three to five years later. That gap is exactly the period in which spontaneous report counts are least interpretable and most quoted.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedMakhmutov A, Qureshi F, Ketoacidosis Risk in Non-diabetic Patients Using Semaglutide Versus Tirzepatide for Obesity - Cureus 2026 (PMID 42299163)pubmed.ncbi.nlm.nih.gov
- PubMedGandhi A et al., Comparative Renal Safety of Tirzepatide and Semaglutide: An FAERS Disproportionality Study - J Clin Med 2025 (PMID 41227073)pubmed.ncbi.nlm.nih.gov
- PubMedShokr H et al., Comparative Safety of GLP-1 Receptor Agonists Across Gastrointestinal, Renal and Pancreatic Systems - Pharmaceuticals 2026 (PMID 41599734)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- The Complication That Hides Behind a Normal GlucoseKetoacidosis with near-normal glucose is easy to miss: the test that usually raises the alarm looks reassuring. Both incretin drugs show reporting signals.
- Disclosure Is Not DisqualificationA 2026 obesity meta-analysis declares its sponsor, its employee authors and its paid contractors in full. That transparency is what makes scrutiny possible.
- GDF15: The Same Signal, Wanted and FearedGDF15 acts on a brainstem receptor to suppress appetite. It is an obesity drug target, a cachexia drug target, and a cause of nausea and vomiting in pregnancy.
- PYY(3-36): The Satiety Signal Scaled to the MealPYY is released from the gut after eating, in proportion to the calories consumed. Its active form is produced by the very same enzyme that destroys GLP-1.
- Leptin: The Discovery That Did Not Become a DrugLeptin took wild-type mice from 12.2% body fat down to 0.7%. It is licensed today for a rare disease affecting a few thousand people, and not for obesity.